Stay updated on Pembrolizumab & Lanreotide for GI NETs Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page.

Latest updates to the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page
- Check6 days agoChange DetectedThe page has been updated to reflect a new version of the study, with significant changes in the study's title and the removal of detailed inclusion and exclusion criteria for participants. The addition of collaborators and specific drug administration details indicates a shift in focus towards the treatment protocol.SummaryDifference42%
- Check13 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check49 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check70 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check78 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check92 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab & Lanreotide for GI NETs Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page.